Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Johnson and Johnson
Harvard Business School
Medtronic
McKesson

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,129,362

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,129,362 protect, and when does it expire?

Patent 8,129,362 protects EPIDUO and is included in one NDA.

This patent has thirty-four patent family members in twenty-two countries.

Summary for Patent: 8,129,362
Title:Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
Inventor(s): Chacra Vernet; Marie-Line Abou (Nice, FR), Gross; Denis (Callian, FR), Loesche; Christian (Valbonne, FR), Poncet; Michel (Mougins, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:11/826,364
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,129,362
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,129,362

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF ACNE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,129,362

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France06 52968Jul 13, 2006

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
Johnson and Johnson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.